Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.
The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.
Hsbc Holdings PLC acquired a new stake in shares of Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 26,394 shares of the company's stock, valued at approximately $760,000. Several other large investors have also
Canada Pension Plan Investment Board acquired a new stake in Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 23,600 shares of the company's stock, valued at approximately $680,000. A number of other hedge funds and other
Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen analysts that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating
AWM Investment Company Inc. bought a new position in shares of Progyny, Inc. (NASDAQ: PGNY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 220,000 shares of the company's stock, valued at approximately $6,343,000. AWM Investment Company Inc. owned about 0.29% of
MNDY, MTCH, PGNY and WK make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.
Bank of America Corp DE boosted its stake in shares of Progyny, Inc. (NASDAQ: PGNY) by 75.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,190,996 shares of the company's stock after acquiring an additional 511,609 shares during the quarter. Bank
